Amal H. Abu Sabaa

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
e14073 Background: FOLFOXIRI demonstrated tolerable toxicities and improved efficacy compared to FOLFIRI in MCRC in a phase III trial. Oral C has demonstrated similar efficacy to IV 5-FU and might(More)
BACKGROUND Intravesical Bacillus Calmette-Guerin (BCG) has been the standard of care for the prevention of nonmuscle invasive bladder cancer (NMIBC) recurrence following resection. Attempts to(More)
  • 1